Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies - Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics
February 05, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies - Ascendis...
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
January 24, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
November 14, 2022 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
October 05, 2022 09:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
July 26, 2022 12:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
May 16, 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 08:00 ET
|
Entera Bio Ltd.
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call...
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
May 05, 2022 08:00 ET
|
Entera Bio Ltd.
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...